| 2012-04-20 |
Alan W. Dunton, M.D., has been a director since June 2011... Member of the Audit Committee and Compensation Committee. Total compensation: $24,976. |
| 2012-07-31 |
Alan W. Dunton, M.D. listed as a director in the beneficial ownership table |
| 2013-05-15 |
Alan W. Dunton, M.D. has been a director since June 2011. He is a member of the audit committee and the compensation committee. For our 2012 fiscal year, Dr. Dunton received an annual retainer of $38,500. |
| 2014-05-06 |
Alan W. Dunton, M.D. has been a director since June 2011... Member of the audit committee and compensation committee... Director compensation table shows total compensation of $64,464. |
| 2015-04-24 |
Alan W. Dunton, M.D. has been a director since June 2011. ... Dr. Dunton has extensive drug development and clinical research experience, having played a key role in the development of more than 20 products to regulatory approval, and also has extensive experience as an executive or officer for large pharmaceutical companies and smaller biotechnology and biopharmaceutical companies. |
| 2016-04-22 |
Alan W. Dunton, M.D. has been a director of Palatin since June 2011. ... (1) Member of the audit committee. (2) Member of the compensation committee. ... Alan W. Dunton, M.D. received $56,000 in fees earned or paid in cash, $21,600 in stock awards, and $13,984 in option awards, totaling $91,584. |
| 2017-04-28 |
Alan W. Dunton, M.D. has been a director of Palatin since June 2011. Since November 2015, he has been senior vice president of research and development for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded company Oragenics, Inc. He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. |
| 2018-05-17 |
ALAN W. DUNTON, M.D., has been a director of Palatin since June 2011... Audit committee composed of Dr. Dunton... Compensation committee composed of Dr. Dunton (chairperson)... Compensation table shows total compensation of $91,476. |
| 2019-05-10 |
Alan W. Dunton, M.D., has been a director of Palatin since June 2011. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From November 2015 through March 2018 he was senior vice president of research, development and regulatory affairs for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded companies Regeneus Ltd, an Australian company traded on the Australian Securities Exchange, Oragenics, Inc. and CorMedix Inc. He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including president and managing director of the Janssen Research Foundation, the primary global R&D organization for Johnson & Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. Dr. Dunton serves on the Audit Committee and the Compensation Committee. For fiscal 2018, Dr. Dunton received total compensation of $150,275. |
| 2020-05-11 |
Alan W. Dunton, M.D., has been a director of Palatin since June 2011. He is a member of the audit committee and the compensation committee. For fiscal 2019, he received total compensation of $170,175. |
| 2021-04-26 |
Alan W. Dunton, M.D., has been a director of Palatin since June 2011... He is a member of the audit and compensation committees. Director compensation table shows total compensation of $150,950. |
| 2022-05-24 |
Alan W. Dunton, M.D., has been a director of Palatin since June 2011. (1) Member of the audit committee. (2) Member of the compensation committee. The following table sets forth the compensation we paid to all directors during fiscal 2021, except for Dr. Spana, whose compensation is set forth below in the Fiscal 2021 Summary Compensation Table and related disclosure. Alan W. Dunton, M.D. 69,750 fees earned or paid in cash, 42,500 stock awards, 42,500 option awards, total 154,750. |
| 2023-05-19 |
Alan W. Dunton, M.D., has been a director of Palatin since June 2011. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From November 2015 through March 2018, he was senior vice president of research, development, and regulatory affairs for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded companies Recce Pharmaceuticals Ltd (ASX: RCE), CorMedix Inc. (NYSE: CRMD) and Oragenics, Inc. (NYSE: OGEN). He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including president and managing director of the Janssen Research Foundation, the primary global R&D organization for Johnson & Johnson. Dr.Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. Dr. Dunton has extensive drug development, regulatory, and clinical research experience, having played a key role in the development of more than 20 products to regulatory approval, and also has extensive experience as an executive and officer for both large pharmaceutical companies and smaller biotechnology and biopharmaceutical companies. |
| 2024-05-28 |
Alan W. Dunton, M.D. has been a director of Palatin since June 2011. He is a member of the audit committee and compensation committee. Compensation table shows total compensation of $112,466. |